Puma biotechnology, inc. (PBYI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Sep'11
Operating activities:
Net loss

-75,595

-113,575

-291,955

-276,011

-239,284

-141,965

-54,659

-74,352

-10,233

-392

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

8,077

7,384

2,811

1,149

776

627

423

265

11

-

Built-out allowance received from landlord

-

-

-

2,997

179

192

-

-464

-439

-

Stock-based compensation

57,327

86,939

108,735

117,264

94,934

39,151

7,519

1,408

67

-

Disposal of property and equipment

-54

-

-

-

-

-

-

-

-

-

Loss on impairment of asset

-1,183

-

-

-

-

-

-

-

-

-

Loss on debt extinguishment

-8,047

-

-

-

-

-

-

-

-

-

Disposal of leasehold improvements

-

-

-

-368

-

-

-

-

-

-

Debt modification fees

-

-289

-

-

-

-

-

-

-

-

Anti-dilutive warrant

-

-

-

-

-

-

-

18,222

7,586

-

Changes in operating assets and liabilities:
Accounts receivable, net

8,123

11,103

9,670

-

-

-

-

-

-

-

Inventory, net

545

596

2,029

-

-

-

-

-

-

-

Other receivables

-

-

-

-

-1,760

-8,053

-799

10,612

-

-

Prepaid expenses and other

-568

840

1,142

-3,413

958

8,584

6,727

707

281

-

Other current assets

-1,464

1,787

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

0

Deposits

-

-

-

-

-

-

-

-

-

9

Accounts payable

-1,526

-7,008

7,657

2,231

2,806

4,305

10,210

395

87

212

Accrued expenses

22,599

15,783

13,222

2,787

-14,805

20,865

-12,640

20,719

500

-

Deferred rent

154

-409

99

-4,112

-124

-153

-27

-186

-

-

Post-marketing commitment liability

9,000

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

22,400

-24,105

-172,470

-141,690

-154,468

-77,203

-55,048

-44,012

-1,824

-190

Purchase of intangible assets

-

-

50,000

-

-

-

-

-

-

-

Purchase of property and equipment

306

439

431

4,287

1,002

1,100

624

591

254

3

Restricted cash

-

-

-

-

3,098

1

2

159

1,053

-

Expenditures for leasehold improvements

-

170

-

2,997

179

192

4

471

439

-

Purchase of available-for-sale securities

127,198

107,502

79,729

81,794

214,806

132,259

49,347

-

-

-

Sale of available-for-sale securities

28,135

-

-

-

-

-

-

-

-

-

Maturity of available-for-sale securities

104,532

50,488

114,724

231,267

133,222

70,277

8,446

-

-

-

Net cash provided by (used in) investing activities

5,163

-57,623

-15,436

142,189

-85,863

-63,275

-41,531

-1,221

-1,746

-

Financing activities:
Proceeds from issuance of stockholder's convertible note payable

-

-

-

-

-

-

-

-

150

150

Net proceeds from issuance of common stock

-

-

-

161,854

205,133

129,440

-

129,214

56,741

0

Net proceeds from shares issued under employee stock plans

1,351

7,652

26,685

576

28,228

6,533

2,215

45

-

-

Proceeds from long-term debt

25,000

105,000

50,000

-

-

-

-

-

-

-

Payment of debt

80,000

-

-

-

-

-

-

-

-

-

Payment of debt extinguishment costs

7,793

-

-

-

-

-

-

-

-

-

Payment of debt issuance costs

5,625

4,201

1,575

-

-

-

-

-

-

-

Capital contributions by stockholder

-

-

-

-

-

-

-

-

61

68

Net cash provided by financing activities

-67,067

108,451

75,110

162,430

233,361

135,973

2,215

129,259

56,952

218

Net increase (decrease) in cash, cash equivalents and restricted cash

-39,528

26,723

-112,796

162,929

-6,970

-4,505

-94,364

84,026

53,382

25

Supplemental disclosures of non-cash investing and financing activities:
Property and equipment purchases in accounts payable

25

-

27

-

-

-

-

-

-

-

Receivables related to stock option exercises

-

-

449

-

-

835

-

-

-

-

Supplemental disclosure of cash flow information:
Interest paid

11,739

8,055

344

-

-

-

-

-

-

-

Conversion of stockholder's note payable to common stock

-

-

-

-

-

-

-

-

150

-